Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Aug 19, 2014

Promega Sets Up Service and Support Office in India

  • Promega opened a new subsidiary in India, Promega Biotech India Private, which will offer services and support for Promega products and technologies.

    “India’s biotechnology industry is one of the fastest growing in the world. The establishment of this branch gives us further appreciation into what is most helpful to customers and it allows us to respond to any specific needs of the region,” said Bill Linton, president and CEO of Promega.

    The Promega India team, led by Rajnish Bharti, Ph.D., general manager, brings its expertise in genomics, proteomics, and cell analysis research, including applied fields of DNA typing, biobanking, and drug discovery, to the new venture, added Linton.

    “Promega India’s team will be a valuable resource for our customers in India and in the Pacific Asia region,” noted Dr. Bharti. “Our branch provides a direct link to the Indian research, development, and business community, allowing us to support scientific initiatives and innovations.”



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »